Kesimpta from Novartis AG - quiet monthly pen for relapsing MS

Kesimpta brings once-monthly self-injection for many patients with relapsing multiple sclerosis, packaged in a handheld autoinjector pen. This bestseller drives the price of Novartis shares (ISIN CH0012005267).

Reviewed: ad hoc news Lifestyle & Consumer desk. Edited and checked on 2026-06-26, 07:11. Details in the imprint.

The Kesimpta autoinjector from Novartis AG sits in the palm like a chunky marker pen, cold from the fridge and with a quiet click when the dose goes in. Many patients with relapsing multiple sclerosis trade monthly hospital infusions for this living-room ritual.

What Kesimpta actually does

Kesimpta is the brand name for ofatumumab, a targeted antibody therapy for adults with relapsing forms of multiple sclerosis. It works by selectively depleting B cells, a type of immune cell involved in the disease process, to reduce relapses and MRI activity. Novartis official product page

After three loading doses in the first month, patients move to a once-monthly 20 mg injection delivered subcutaneously via the prefilled Sensoready pen. The drug is approved in the EU and US for relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.

Monthly pen instead of infusion chair

Neurologist Prof. Gavin Giovannoni has described Kesimpta as a way to bring high-efficacy B-cell therapy into the home, avoiding infusion centers for many suitable patients. Commentary on the FDA approval

The disposable pen is designed with a rounded body and a flat side that rests against the thigh or abdomen. Patients hear a muted mechanical sound as the spring mechanism fires, feel a short sting, and then watch the viewing window to confirm completion.

Efficacy and safety profile

In the pivotal ASCLEPIOS I and II trials, Kesimpta showed a lower annualized relapse rate and reduced MRI lesion activity compared with the oral drug teriflunomide in adults with relapsing MS. New England Journal of Medicine study

Serious infections and injection-related reactions are key safety watchpoints. Patients typically undergo screening for hepatitis B and other infections, and doctors such as Novartis development chief Dr. John Tsai stress the need for regular monitoring of immune parameters.

How it fits into the MS toolbox

Kesimpta competes with other high-efficacy MS therapies such as ocrelizumab, natalizumab, and oral sphingosine-1-phosphate modulators. Its once-monthly at-home dosing gives it a practical edge for patients who value fewer clinic visits.

For neurologists, the balance is between potency, safety, and patient preference. Some will still favor infusion-based therapies for specific cases, while others see the pen as a way to initiate strong treatment earlier in the disease course.

Pricing and access in Europe

In major European markets, Kesimpta is typically reimbursed within national health systems for eligible adults with active relapsing MS after health-technology assessment processes. List prices vary, but the therapy sits firmly in the high-cost biologics segment.

For patients, that often translates into low direct co-payment but strict eligibility criteria and paperwork. Patient advocates note that the home-injection format reduces travel and time off work, which is relevant for younger adults living with MS.

Patient experience and handling

Before the first dose, nurses usually walk patients through practice injections on a dummy pad. The cold plastic, the audible click, and the brief burn of the fluid become familiar, and some users describe timing their injection to a favorite TV show as a monthly anchor.

The pen must be stored refrigerated and protected from light, then warmed to room temperature for around 15 minutes before use. For people sharing a small flat or dorm, that means a noticeable medicine box in the fridge and a reminder of the diagnosis every time they reach for milk.

Where Kesimpta falls short

Kesimpta is not a cure for MS, and disability can still progress despite fewer relapses. Some patients experience injection-site reactions, headaches, or upper respiratory infections that make the monthly routine more demanding.

The need for regular blood tests and occasional imaging remains. For a fraction of users, the anxiety around managing a powerful immunotherapy at home is high enough that they prefer supervised infusions despite the travel burden.

Novartis and the share price

All told, Kesimpta sits alongside oncology and radioligand therapies as one of the newer growth drivers in the Novartis portfolio, even as older blockbusters face generic pressure. Recent revenue commentary

On SIX Swiss Exchange, Novartis shares (ISIN CH0012005267) trade in Swiss francs and remain one of the core blue chips for Swiss institutional and retail investors watching the company’s pipeline progress.

Key facts on Kesimpta

• Product: Kesimpta autoinjector (ofatumumab)
• Manufacturer: Novartis AG
• Category: Lifestyle/Consumer - prescription biologic therapy
• Launch: Initial FDA approval in 2020 for relapsing MS
• RRP / Price: High-cost biologic, reimbursed pricing varies by market (CHF/EUR range, not usually paid fully out-of-pocket)
• Availability: Prescription-only in the US, EU and other selected markets via neurologists and specialty pharmacies
• Target group: Adults with relapsing-remitting MS, active secondary progressive MS, or clinically isolated syndrome requiring high-efficacy therapy
• Highlight / USP: Once-monthly at-home B-cell therapy using a prefilled autoinjector pen instead of regular infusion visits

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.